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Vascular density in melanoma xenografts correlates
with vascular permeability factor expression but not
with metastatic potential
JR Westphal, RGM van't Hullenaar, JAWM van der Laak, IMHA Cornelissen, LJM Schalkwijk, GNP van Muijen,
P Wesseling, PCM de Wilde, DJ Ruiter and RMW de Waal
Department of Pathology, University Hospital Nijmegen, PO Box 9101, 6500 HB Nijmegen, The Netherlands
Summary We studied the relation between tumour vascular density and tumour growth rate, metastatic incidence and vascular permeability
factor (VPF) mRNA levels in a human xenograft model described previously. Vascular density was determined by automated image analysis.
Xenografts derived from cell lines BLM and MV3 showed the highest mean vascular density (MVD), the highest in vivo growth rate, high VPF
mRNA levels and rapid development of lung metastases. Xenografts of cell lines M14, Mel57 and MV1 showed a significantly lower degree of
vascularization, lower in vivo growth rates and lower levels of VPF mRNA, but formed lung metastases with a similar incidence as those of BLM
and MV3. Xenografts from cell line 1F6 did not form lung metastases, whereas tumours derived from a spontaneous mutant of 1F6, designated
1F6m, gave rise to lung metastases to the same extent as Mel57, M14 and MV1 tumours. MVD values in 1 F6 and 1F6m xenografts, VPF
mRNA levels and in vivo growth rates of 1F6 and 1F6m xenografts, however, were similar. In conclusion, in the melanoma xenograft model
vascular density is correlated with in vivo growth rate and with in vitro VPF mRNA levels, but not with the ability to metastasize.
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As in any other living tissue, tumours require a blood supply suffi-
cient for their maintenance and growth. In addition to delivering of
oxygen and nutrients to the tumour, the tumour vasculature also
functions as an escape route formetastasizing tumourcells. In 1971,
Folkman postulated that solid tumours are dependent on angiogen-
esis for sustained growth (Folkman, 1971). Later studies suggested
that tumours possessing the capacity to induce angiogenesis and
neovascularization may be associated with a malignant phenotype
[reviewed by Liotta et al (1991) and Weinstat-Saslow and Steeg
(1994)]. In accordance with this view, the vascular density of a
number oftumourtypes has been described recently to bepredictive
forthe metastatic capacity oftheprimary tumour, and tumourangio-
genesis is nowadays recognized as an important factor in tumour
biology (Folkman, 1995a, b). A correlation between high vascular
density andtheoccurrence ofmetastases andpoorclinical prognosis
has beenreported forbreast cancer (Weidneretal, 1991; Horaketal,
1992), prostate cancer (Wakui et al, 1992; Bigler et al, 1993;
Weidner et al, 1993), non-small-cell lung carcinoma (Macchiarini et
al, 1992), malignant melanoma (Srivastava et al, 1988; Smolle et al,
1989; Graham et al, 1994) and many other types of malignancies
(recently reviewed by Weidner (1995), although in the case of
malignant melanoma there is controversy (Barnhill et al, 1994;
Busam et al, 1995). The mechanisms that a tumour can employ to
increase the number ofblood vessels are diverse and notcompletely
understood. Angiogenesis involves the breakdown of the basal
lamina that surrounds a blood vessel, migration and proliferation of
endothelial cells, and organization of a new vessel structure.
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Tumour-derived factors can influence each ofthese steps (Folkman
and Shing, 1992; Albelda, 1993). The most prominent feature that
facilitates angiogenesis is the production of angiogenic factors by
tumourcells. Sofar, about 20factors thatinfluence in vitro and/orin
vivo aspects of angiogenesis have been reported (Folkman and
Klagsbrun, 1987; Klagsbrun and D'Amore, 1991). Among the most
effective ofthesefactors arethefibroblastgrowth factors (aFGFand
bFGF) and vascular permeability factor (VPF, also known as
vascular endothelial growth factor orVEGF) (Potgens et al, 1995a).
The ability ofatumourto form metastases depends on itsexpression
ofproteases thatdegrade extracellular matrix, inparticular the basal
lamina surrounding blood vessels, and the expression of adhesion
molecules that enable tumour cells to adhere to either components
ofthe stroma and basal lamina or to endothelial cells.
We studied the relation between tumour angiogenesis and
metastatic potential ofhuman malignant melanoma in apreviously
described xenograft model (VanMuijen etal, 1991a,b). The model
consists of a panel of cultured melanoma cell lines, which form a
local tumour after subcutaneous injection into nude mice. The
resulting xenografts differ in growth rate and in capacity to form
spontaneous lung metastases. In this paper we correlate the
xenograft (micro)vascular density with metastatic behaviour, the
in vivo and in vitro growth rates ofthe melanoma cell lines and the
expression level ofVPF mRNA.
MATERIALS AND METHODS
Cell lines
Cell lines 530, 1F6, M14, Mel57, MV1, MV3 and BLM were
derived from surgically removed human melanoma metastases, as
described previously (Van Muijen et al, 1991a,b; Weterman et al,
1992). Cells were cultured in Dulbecco's Modified Eagle Medium
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(DMEM) with glutamine (Biowhittaker, Walkersville, MD, USA),
supplemented with 10% fetal calfserum (FCS) (Integro, Zaandam,
The Netherlands) and antibiotics in Nunc culture flasks (Roskilde,
Denmark). During our experiments, we found large numbers of
metastases in the lungs of numerous mice inoculated with 1F6
cells, whereas this cell line had only sporadically given rise to
metastases previously. When repeating the experiments with an
old stock of 1F6 we found no lung metastases, indicating the spon-
taneous conversion of 1F6 towards a metastasizing phenotype. We
therefore designated the mutant cell line lF6m. To determine
whether 1F6 and lF6m indeed shared the same genetic back-
ground, the length of eight different hypervariable CA repeats on
different chromosomal loci was determined by specific PCR on
DNA isolated from both 1F6 and lF6m, as described previously
(Nelen et al, 1994). The number ofCA repeats on all investigated
loci was identical (data not shown). These data indicate that both
cell lines have a common genetic background, and that lF6m is a
true descendant from 1F6.
Mice and xenografting procedure
Human melanoma cell lines were xenografted in BALB/C nu/nu
mice kept under aseptic conditions. Cultured cells were detached
from the culture flask by treatment with a trypsin/EDTA/glucose
solution, washed with phosphate-buffered saline (PBS) and
injected s.c. into the flank of the mice in a volume of 100gl of
PBS. At least 50 mice per cell line were inoculated in total and
killed at different time points after take ofthe primary tumour. To
obtain 100% tumour take, high numbers ofcells (3 x 106 forBLM,
MV3, MVl and M14, 4 x 106 for IF6, lF6m and Mel57, and
5 x 106 for 530) were injected. Tumour take was determined by
palpation ofthe inoculation site. The volume ofthe s.c. tumour at
autopsy was estimated by multiplying length, width and height of
the tumour mass. The s.c. tumour and parts of spleen and liver
were removed and fixed in formalin. The lungs wereperfused with
a 1:5 mixture of water and Tissuetec (Miles Diagnostics Division,
Elkhart, IN, USA), and formalin fixed. Parts ofthe tumour and the
lungs were snap-frozen and stored in liquid nitrogen. No metas-
tases were ever observed in tissue sections ofspleen and liver.
Determination of metastatic burden
Tissue cross-sections of formalin-fixed lungs were cut at two
levels (at about one-third and two-thirds of the height of the
lungs), stained with haematoxylin and eosin, and scored micro-
scopically for the presence of lung metastases. The number of
metastases was determined, and the area of the lung sections and
of the metastases was measured with the aid of semiquantitative
image analysis system (MOP Videoplan, Kontron, Eching,
Germany). Metastatic burden was defined as the area occupied by
metastases in relation to the total area ofthe lung sections.
Staining and quantitation of tumour vasculature
Vessels in melanoma xenografts were stained immunohistochemi-
cally and quantified using an interactive automated image analysis
system, as described elsewhere (van der Laak et al, submitted for
publication). Briefly, frozen tissue sections were incubated with rat
anti-mouse endothelial cell MAb 9F1 (a generous gift from
Dr A Hamann, Hamburg, Germany), followed by an alkaline phos-
phatase-labelled secondary antibody. After colour development,
microscopic images were recorded by a video camera with a 1Ox
objective. Stained vessels were recognized by the VIDASP'us
image analysis system (Kontron), with the aid of specially devel-
oped software. After interactive correction for staining irregulari-
ties, the mean vascular density could be determined for each
tumour section. Between 3.2 and 10 mm2 of viable tumour tissue
per section was analysed.
MTT assay
In vitro growth rates ofmelanoma cell lines were determined with
the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium
bromide) cell proliferation kit (BoehringerMannheim, Mannheim,
Germany). The MTT assay was calibrated by performing an MTT
assay and a conventional cell proliferation assay (performed by
direct counting of cell numbers with the aid of a Coulter counter)
in a parallel fashion. Both assays resulted in similar proliferation
curves (data not shown). The MTTassay was performed according
to the manufacturer's instructions. Briefly, cells were cultured for
different periods of time in 100 ,l of culture medium in 96-well
microtitre plates (Costar, Cambridge, MA, USA) before addition
of 10 p1 of5 mg MTT per ml ofPBS solution. After an incubation
period of4 h, 100gl oflysis buffer (10% SDS/0.01 N hydrochloric
acid) was added to each well. The presence oftetrazolium salt was
measured spectrophotometrically at 540 nm, with 690 nm as refer-
ence wavelength.
RT-PCR for VPFNEGF mRNA
Total RNA was isolated from cultured melanoma cell lines with an
isolation kit purchased from Qiagen (Chatsworth, CA, USA).
Conversion of VPFNEGF mRNA to cDNA was performed using
a specific antisense primer (5'-TTCCTCCTGCCCGGCTCACCG-
3') and avian myeloblastosis virus (AMV) reverse transcriptase
(Promega, Madison, WI, USA). Subsequently, 35 PCR cycles
were performed with the above-mentioned primer and 5'-CCCG-
GTCGGGCCTCCGAAACCA-3' as sense primer, at an annealing
temperature of 68°C. This procedure resulted in three bands of
500, 610 and 670 bp on agarose gel, corresponding to the mRNA
species coding for VPF'21, VPF'65 and VPF'89 respectively. The
specificity of the RT-PCR procedure was checked by blotting the
PCR products on nitrocellulose and probing this blot with a full-
length VPF165 cDNA probe. All three PCR products reacted
strongly with this probe, but not with cDNA probes for bFGF or
IGF-I (data not shown).
Quantitative RT-PCR
Quantification of the PCR products was performed basically as
described by Mentzel et al (submitted for publication) for the
quantification ofaminopeptidase A (APA) mRNA. Briefly, a 250-
bp fragment was deleted from the VPF165 cDNA. The truncated
fragment was cloned into a vector containing SP6 and T7 RNA
polymerase start sites using the Invitrogen TA cloning kit (San
Diego, CA, USA). The insert of this construct can be amplified
with the original primer combination, resulting in a 350-bp
product. After determination ofthe insert orientation by restriction
analysis, synthetic sense mutant RNA was produced using the
appropriate RNA polymerase. Various concentrations of this
synthetic competitor RNA were mixed with a fixed amount of
sample (cell line) RNA (1 tg per reaction), and RT-PCRs were
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performed as described above. In these reactions, the synthetic
RNA competed with the wild-type RNA for enzymes and
nucleotides, resulting in the formation of decreasing amounts of
wild-type PCR products with increasing amounts of mutant
(competitor) RNA. Wild-type PCR products and mutant PCR
product were separated on agarose gel (the mutant product being
150 bp smaller than the smallest wild-type product), and stained
with ethidium bromide. The intensities of the stained bands were
measured. The amount of VPF mRNA in the sample RNA was
quantified by determining the concentration of synthetic RNA in
which the intensity ofthe mutantproduct bandequalled the sum of
the intensities ofthe bands ofthe wild-type products.
Statistical analysis
Non-linear (in vivo growth rates ofxenografts) and linear (relation
MVD and tumour age or tumour volume; calibration curves of
quantitative RT-PCR for VPF mRNA) regression analysis was
performed with the aid of the GraphPad Prism software package
(GraphPad Software, San Diego, CA, USA). Mean vascular
density values of the xenografts were evaluated with Dunn's
multiple comparisons test, and in vitro VPF mRNA levels with the
Tukey-Kramer multiple comparisons test.
RESULTS
Vascularization of melanoma xenografts
We analysed the vasculature of xenografts of the different cell
lines by staining tumour tissue sections with 9F1, a rat monoclonal
antibody directed against mouse endothelial cells. To confirm the
endothelial cell (EC)-specificity of MAb 9F1, we compared 9F1
staining of tissue sections of several normal mouse tissues and
melanoma xenografts with the staining by anti-mouse endothe-
lium-specific MAb MEC 7.46 raised and characterized by Vecchi
et al (1994). In normal mouse tissues, 9F1 was less specific for
endothelial cells than MEC 7.46, but in xenograft sections 9F1
reacted only with endothelial cells (data not shown). We chose 9F1
for further analysis because 9F1 stained ECs with a higher inten-
sity than MEC 7.46, which was of importance for the subsequent
image analysis process. Representative examples of M14 and
MV3 xenografts stained with 9F1 are shown in Figure 1. Viable
tumour tissue in xenografts from all the cell lines was almost
exclusively confined to the periphery of the tumour, especially in
tumours larger than 1 cm3. Observations were therefore confined
to this region ofthe tumours. In xenografts derived from cell lines
1F6, lF6m, MV1, M14 and Mel57, the number ofvessels per area
unit was low compared with BLM and MV3 tumours. The vessels
were relatively large, and were surrounded by a cuff of viable
tumour tissue. These viable tumour 'islands' were surrounded by
large necrotic areas. Xenografts of MV3 and BLM demonstrated
a higher number of vessels per area unit, and necrosis in the
tumour periphery was relatively rare. The percentage of small
vessels in these xenografts was relatively high in relation to the
total number vessels.
We quantified our observations on vessel numbers by semi-
automated image analysis oftissue sections stained with 9F1. This
approach enabled us not only to study the number of vessels per
surface unit, but also to measure parameters such as vessel area
and diameter. The results, expressed as mean vascular density
(MVD), are shown in Figure 2. The overall mean vascular density
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Figure 1 Tissue sections of xenografts stained with rat anti-mouse EC MAb
9F1 and a weak haematoxylin counterstaining. M14 xenograft (A) shows few
vessels that are surrounded by a cuff of viable tissue. MV3 xenograft (B)
shows a high vascular density without necrosis and with many small vessels.
Bar represents 50,m
values of all analysed xenograft specimens are shown in Table 1.
From each xenografted cell line, at least nine specimens of
different age were analysed, and from each specimen at least 20
microscopic fields, corresponding to 3.2 mm2 of viable tumour
tissue, were measured. No correlation was found between age of
the xenograft and MVD (data not shown). Statistical comparison
ofMVD values ofBLM and MV3 xenografts vs MVD values 1F6,
lF6m, M14, Mel57 and MVI is shown in Table 1. MVD values
did not differ significantly among the last five cell lines in any of
the vessel diameter classes (data not shown). Xenografts derived
from cell line 530 were omitted from the analysis because they
were too small or too necrotic to obtain reliable data.
When analysing all vessels without selection, a clear difference
in MVD between xenografts from cell lines 1F6, lF6m, M14, MVI
and Mel57 on one hand, and BLM and MV3 on the other could be
observed (Figure 2A). Xenografts of the first group possessed
similar vascular densities, with mean values between 42.1 (M14)
and 62.5 (MV1) vessels mm-2 (Table 1), with 100 vessels mm-2 as
maximum value. Both BLM and MV3 showed higher vascular
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Figure 2 Mean vascular densities in xenografts derived from the panel of melanoma cell lines, as determined by automated image analysis. Vessels were
divided in different size classes based on their diameter (as indicated in each case) and analysed separately. Each circle represents the MVD of a xenograft.
MVD of mice without (0) and with (0) lung metastases. Horizontal line in each column represents the mean
densities, with mean values of 139.6 and 129.2 vessels MM-2 (Table
1), ranging from 36 to 347 (BLM) and from 62 to 271 (MV3)
vessels MM-2. In BLM and MV3 xenografts, the data were spread
over a large range and showed partial overlap with MVD values
from the other five xenograft types. Next, we analysed subsets of
vessels based on their diameter. Boundaries of the investigated area
classes were determined on the basis of morphological criteria.
Vessels with diameters of less than 3 jim, 3-6 jim, 6-12 jim and
more than 12 gim, roughly corresponded morphologically to vessel
cross-sections smaller than a capillary, capillaries, arterioles and
venules, and to larger vessels respectively. Vascular counts of larger
vessels (> 12 jim) and of objects that were too small to be capil-
laries, and which possibly represented vascular sprouts (<.3 jim),
did not discriminate between the different groups of xenografts
(Figure 2F and B respectively). The number of vessels in the 3-
6 jim and the 6-9 jim diameter classes, representing the two
largest vessel subsets, proved to be the most informative in discrim-
inating between the degree of vascularization of BLM and MV3
on one hand, and 1F6, lF6m, MV1, M14 and Mel57 on the other
hand (Figure 2C and D and Table 1). In the 9-12 jim class the
differences between BLM and MV3 xenografts, and xenografts
derived from lF6m and Mel57 became less marked, but still highly
significant for xenografts derived from I1F6, M14 and MV1I (Figure
2E, Table 1).
Next, we investigated whether the observed differences in
vascular densities in the xenografts correlated with other parameters
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Figure 3 In vitro proliferation of human melanoma cell lines
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ofmalignancy (in vivo growth rate, ability to form spontaneous lung
metastases), and the expression level ofVPF.
In vitro and in vivo growth rate of melanoma cell lines
The melanoma xenografts displayed different in vivo growth rates.
To investigate whether this could be attributed to an intrinsic
proliferation rate of the cell lines, or that environmental factors
were involved as well, wecompared the in vitro and in vivo growth
rates of cell lines and xenografts respectively. The in vitro growth
rate was determined in the MiT assay with different starting cell
densities. Figure 3A shows that 530 and 1F6 cells did not grow
when seeded at low density (1500 cells cm-2). lF6m started to
grow after an initial lag period, whereas the other cell lines showed
similar proliferation rates. When cells were seeded at a higher
density (6000 cells cm-2), all cell lines showed growth, but 530 and
1F6 grew markedly slower than the other cell lines. lF6m prolifer-
ated faster than 530 and 1F6, but not as fast as the other lines.
The in vivo growth rate was determined by estimating the
tumour volume at the day of autopsy. The highly vascularized
BLM and MV3 xenografts showed by far the quickest expansion
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Figure 4 Growth curves of s.c. melanoma xenografts in vivo. Each point
represents the volume of a single xenograft measured at autopsy. Non-linear
regression analysis was performed for each data set
(Figure 4). After a maximum of 6 weeks, the xenografts had
grown to a size when killing ofthe mice could no longer be post-
poned. A total of 530 xenografts grew relatively slowly. Most
tumours were still less than 1 cm3, 2-3 months after take of the
tumour. Xenografts of the other cell lines showed intermediate
growth rates. Remarkably, 1F6 xenografts reached larger volumes
than lF6m xenografts, despite the fact that 1F6 showed a lower in
vitro proliferation rate. In the category of BLM and MV3
xenografts, no correlation was found between MVD and tumour
volume or age (data not shown).
Formation of lung metastases by melanoma xenografts
The occurrence of lung metastases was determined by screening
two tissue sections oflung cross-sections, one at one-third and one
at two-thirds of the height of the lungs. Examination of a larger
number oftissue sections from more levels ofthe lungs had shown
that > 95% of metastasis-positive lungs were detected in this way
British Journal ofCancer (1997) 76(5), 561-570
A 250
2000
16w
iooo
500
B 2500
2000
11500
8 1000
500
;-
E
E
cm
0
a)
E
0
E
n '. . -1 .
51
W-W-
..I
0CancerResearch Campaign 1997Angiogenesis in human melanoma xenografts 567
20 530 20 1F6
(n=51) (n=67)
15 15
10 10
5 5
1012 34567 891011 >11 1 2 45678910 11>11
20 1 F6m 20. MV1
(n=75) (n=59)
15 151
0 1
E 20 M14 20 Mel57
z3 (n=63) (n=67)
A fg competitor RNA
;g co co
_ I I I
wRNA -a
cRNA
-
B
Z Z
Ce 3
Ce .s X l r_
.0,
e
r-
log (fg compettor RNA)
C
Weeks after take of subcutaneous tumour
Figure 5 Analysis of lung (micro)metastasis formation in xenograft-bearing
mice. At different time points after tumour take, mice were killed and the
lungs were examined microscopically for the presence of lung
(micro)metastasis. Note that in mice bearing 530 or 1 F6 xenografts hardly
any metastatic lesions were found in the lungs, whereas mice with
metastases were numerous in the other groups. The presence of metastasis
could be detected as early as 2 weeks (BLM) after tumour take. Number of
mice without (E) and with (M) lung (micro)metastases
(data not shown). Both the number of metastases and the area of
the metastases relative to the area ofthe lungs were determined. In
all eight xenograft types, a large range was observed both in the
number of metastases per lung and in the size of the metastases.
No evident differences between number of metastases or
metastatic burden could be observed between mice carrying
xenografts derived from different cell lines (data not shown). Also,
no correlation was found between tumour age and metastatic
burden in any investigated cell line. It should be noted that most
lung metastases were not detectable macroscopically.
Although number and size ofmetastases were similar among the
various groups, we did observe differences in the time points after
tumour take at which lung metastases were first observed. Figure 5
shows the occurrence of lung metastasis in mice carrying
xenografts of different ages. As early as 10 days after take of the
s.c. tumour, micrometastases could be found in mice bearing BLM
xenografts. When the tumours had reached their maximal volume,
in 60-70% of these mice lung metastases were found. Although
metastases formation was somewhat slower in mice carrying
xenografts from lF6m, Mel57 or M14, the percentage of meta-
stasis-positive mice eventually became as high as, or even higher
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Figure 6 Example of quantitative determination of VPF mRNA levels in
BLM. (A) Products of RT-PCR performed with 1 9g of BLM RNA and
increasing amounts of competitor RNA. Products were run on a 1% agarose
gel and stained with ethidium bromide. Products of 670, 610 and 500 bp are
derived from wild-type VPF mRNA (wRNA), the product of 350 bp is derived
from competitor RNA (cRNA). The concentration of cRNA increases from left
to right, with a fixed amount of sample RNA, resulting in an increasing
amount of amplified cRNA accompanied by a decreasing amount of amplified
w-VPF mRNA. Each measurement was performed in duplicate. (B) log(cRNA
concentration) plotted against log(ratio band intensities of wRNA
products/band intensity cRNA product). VPF mRNA concentration in samples
can be extrapolated from the plot at log(ratio) = 0. (C) Results of quantitative
VPF mRNA determinations. Two batches of RNA of each cell line were
tested, each batch was tested twice. RNA batch 1, El; RNA batch 2, c
than, that ofmice carrying BLM or MV3 xenografts. In the case of
Mel57, up to 100% of mice were found to have lung metastases
when killed 8 weeks after tumour take. Mice carrying 530 or 1F6
xenografts only sporadically (1 out of 51 and 3 out of 67
respectively) developed lung metastases. In these four mice, the
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metastatic burden was very low; only one or two micrometastases
per section and never more than ten tumour cells per metastatic
lesion were observed.
We looked for a possible correlation between the vascular density
ofBLM and MV3 xenografts and the presence or absence of metas-
tases or the metastatic burden. No statisticaly significant differences
could be observed between MVD values in xenografts of mice
without or with lung metastases (Figure 2). Also, no correlation was
found between MVD and metastatic burden (data not shown).
Quantification of VPF mRNA in melanoma cell lines
In a previous study, we showed by Northern blot analysis that VPF
is expressed by cell lines BLM and MV3, but not by cell lines 1F6
and Mel57 (Potgens et al, 1995b). When performing an RT-PCR to
detect VPF mRNA, positivity was found in RNA samples from all
cell lines (data not shown), indicating that VPF mRNA was
expressed by all cell lines but in some cell lines was apparently
below the detection level of Northern blot. To substantiate these
findings, we developed a quantitative RT-PCR for VPF mRNA.
Figure 6A shows the products of a series of RT-PCRs after
separation on agarose gel and staining with ethidium bromide.
After measuring the intensities of the bands, log (concentration
competitor RNA) was plotted against log (ratio ofband intensities)
(Figure 6B). Only experiments with a correlation coefficient of the
resulting graph > 0.95 were used. The amount of wild-type VPF
mRNA in the sample RNA could be extrapolated by determining
the RNA concentration at log (ratio ofband intensities) = 0 (Figure
6B). In Figure 6C, results of mRNA concentration determination
for two separate experiments are shown. The amount of mRNA in
the highly vascularized cell line MV3 was significantly higher than
in I F6, IF6m, Mel57, M14 (P < 0.001) and BLM (P < 0.05). VPF
mRNA concentrations in BLM were significantly higher compared
with those in 1F6, lF6m, M14 and Mel57 (P < 0.05).
DISCUSSION
In this paper we elaborate on a previously described xenograft
model in which human melanoma cells, propagated as cell lines in
vitro, are injected subcutaneously into nude mice.
We have measured the vascular densities of xenografted s.c.
melanoma tumours. As opposed to most other reports on quantifi-
cation of the tumour vasculature, we have used automated image
analysis of a relatively large tumour area instead of manually
selecting one or a few microscopic fields with the highest vascular
density (the hotspot' method) as a parameter for determining the
vascularity ofour tumours. Although we have found (van der Laak
et al, submitted for publication) that in our model there is a good
correlation between the results of both methods, there are three
reasons for using automated image analysis of a large tumour area
instead of hot spot density measurements. First, automated image
analysis allows one to include vessel parameters, such as vessel
diameter in the analysis of the obtained data. As we have shown,
vessels of a certain diameter (corresponding by morphological
criteria to capillaries), discriminated best between the different
groups of xenografts. Second, when assessing the effect of vascu-
larization on the tumour growth rate, the vascularity of the entire
tumour (the MVD) will contribute and has to be taken into
account. Third, angiogenic hot spots may be more objectively
determined by image analysis than by manual selection (van der
Laak et al, submitted for publication). Angiogenic hot spots in a
tumour may be decisive in determining the metastatic behaviour,
as only part ofthe tumour has to be highly vascularized to increase
the probability of metastasizing tumour cells to enter the blood-
stream, especially if tumour cells with a metastasizing phenotype
are located within this hotspot.
We found that, in BLM and MV3 xenografts, MVD values of
vessels between 3 and 12 ,um were 2-4 times higher than those of
the other cell lines. Analysing subclasses of vessels based on their
diameter distinctly enhanced the differentiation into different
degrees of vascularization. M14 showed a distinctively lower
vessel density than BLM and MV3 in all investigated vessel diam-
eter classes. In the case of Mel57, the difference was most
apparent in the 3-6 ,um class, whereas 1F6 and MVl showed the
most pronounced differences in the 6-12 gm class.
BLM and MV3 distinguished themselves from the other cell
lines in displaying a higher in vivo growth rate, and BLM by
formation of spontaneous lung metastases soon after take of the
s.c. tumour (8-15 days). The number and size of the lung metas-
tases formed in mice with M14 or Mel57 xenografts were similar
to those found in mice carrying BLM xenografts, but they
appeared later after tumour take. Lack of correlation between
vessel density and metastatic potential was also demonstrated by
xenografts derived from 1 F6 and its spontaneous descendant
lF6m. These xenografts display vascular profiles that are quantita-
tively and qualitatively identical, but in IF6m-bearing mice
numerous spontaneous lung metastases were observed, whereas
1F6 xenografts only sporadically metastasized. We conclude that
in our model system a high MVD correlates with an increased rate
of in vivo proliferation and with faster metastasis formation, but
not with the event of metastasis formation per se. Whether the
rapid metastasis formation in BLM and MV3 xenografts is a direct
consequence of the high vessel number cannot be concluded from
our data. Obviously, the rapid growth rate of the xenografts results
in a higher number of cells that have the opportunity to metasta-
size. Alternatively, the intrinsic properties of different types of
tumour cells may be the cause of different metastasis formation
speeds. Previous studies have shown that BLM and MV3 differ
from the other cell lines with respect to factors that influence the
metastatic process. They show a strong adherence to extracellular
matrix components laminin and collagen types I and IV (Danen et
al, 1993, 1995), and have a high expression level of the extracel-
lular protease urokinase-type plasminogen activator (uPA) and its
inhibitor PAI-I (Quax et al, 1991; Van Muijen et al, 1995). The
formation ofexperimental lung metastasis may be used as an indi-
cator of the metastasizing capacities of a cell line. This capacity
was investigated by van Muijen et al (1991a) for cell lines 530,
1F6, M14, Mel57, MV3 and BLM. All lines, with the exception of
1F6, were able to form experimental lung metastases with an effi-
ciency ranging between 50% and 90%, with the highest percent-
ages found in mice injected with BLM or MV3. This superior
intrinsic metastatic capacity of circulating BLM and MV3 cells
may have contributed to the higher speed of metastasis formation
we observed for these cell lines.
The relationship between vascular density and malignancy in
human melanoma is currently under debate. Whereas preliminary
studies indicated that microvessel density in these tumours corre-
lated with their potential to invade and metastasize (Srivastava et
al, 1988; Barnhill et al, 1992; Graham et al, 1994), other reports
could not confirm this (Carnochan et al, 1991; Barnhill et al, 1994;
Busam et al, 1995). In our model system, there was no correlation
between vascular density and the ability to metastasize as well.
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One should bear in mind, however, that s.c. human tumours that
are grown in nude mice are not fully comparable to human
primary melanomas with respect to location (subcutaneous vs
intra(epi)dermal), origin (inoculation with a bulk of cultured cells
vs mono- or oligoclonal expansion) and source ofthe vascular bed
(mouse vs human).
Our current and previous data (Potgens et al, 1995a) have shown
that BLM and MV3 show an expression level of VPF protein and
mRNA that is clearly elevated compared with the cell lines that
generate poorly vascularized tumours, emphasizing the previously
described role (Folkman and Klagsbrun, 1987; Leung et al, 1989;
Klagsbrun and D'Amore, 1991) of this factor in the angiogenic
process. Potgens et al (1995b, 1996) transfected the low VPF-
producing cell line Mel57 with the VPF'2' gene, resulting in a cell
line with an in vitro expression level ofthis VPF isoform that was
1000-fold higher than in the parental cell line. Xenografts derived
from the transfected cell line showed a vascular pattern that was
dramatically changed compared with parental cell line xenografts.
In the parental xenografts vessels were scattered randomly
throughout the tumour, whereas in the mutant xenografts tumour
nodules were surrounded by highly vascularized septa. Frequency,
size and time point of occurrence of spontaneous lung metastases
did not differ in mice bearing either xenograft. Complementary
data were recently presented by Claffey et al (1996). Inoculation of
mice with melanoma cell line SK-Mel-2 transfected with mouse
VPFI64 cDNA, resulted in highly vascularized tumours with an
increased growth rate compared with tumours derived from mock-
transfected cells. Moreover, VPF-transfected cells showed an
increased ability to form experimental lung metastases after i.v.
injection. The effect of transfection with VPF on the formation of
spontaneous lung metastases was not assessed in this study. As
angiogenesis in unlikely to play a role in the initial take and growth
of (micro)metastases, the mechanism by which VPF increased
metastatic potential remains unclear. It is possible that the perme-
abilization effect of VPF on the vessel wall leads to a facilitated
extravasation of tumour cells. This possibility, however, does not
explain why increased metastatic incidence was not observed in
the experiments with VPF-transfected melanoma cell lines
described by Potgens et al (1996), as VPF'2' is a potent inducer of
vessel permeability. Further data on the role of VPF in angiogen-
esis and metastasis formation come from the observation that VPF
mRNA is induced in 1F6 and Mel57 xenografts because of
hypoxic conditions (Potgens et al, 1995b). This up-regulation,
however, did not lead to increased vascular densities in 1F6 and
Mel57 xenografts, it did not induce metastasis formation in 1F6
bearing mice and it did not increase speed of metastasis formation
in Mel57 mice. It is reasonable to assume that also in 530, 1F6m,
M14 and MV1 xenografts, VPF mRNA expression is up-regulated
because of hypoxic conditions. In these cell lines no effect on
MVD and/or speed of metastases formation was found compared
with BLM and MV3. Taken together, these data show that VPF
may be required for, and/or augments the vascularized phenotype
and the metastatic potential of a melanoma xenograft, but may
have to act in concert with one or more other (angiogenic) factors.
To shed more light on this issue, we are currently investigating the
expression levels of a panel of other angiogenic factors on protein
and mRNA level in both the melanoma cell lines and in the corre-
sponding xenografts.
In this paper we have analysed some aspects of tumour angio-
genesis in an in vivo model for human melanoma. Although in this
model a vascular bed of murine origin is generated by human
angiogenic factors, rapid tumour growth and metastatic spread
occur, apparently unhindered by the species barrier, thereby
confirming the suitability of the model to study the process of
angiogenesis. Both the vascularity of the xenografts and the
metastatic burden can be easily quantified in a standardized
manner. Considering the different vascular densities we found in
xenografts derived from the different cell lines, this model
provides us with material that is well suited to investigate the
mechanisms that are responsible for this increased vascular
density. Furthermore, our model may allow for testing the in vivo
effects of antiangiogenic drugs on tumour growth and vascular
densities in a preclinical setting.
ABBREVIATIONS
bFGF, basic fibroblast growth factor; EC, endothelial cell; MAb,
monoclonal antibody; MVD, mean vascular density; RT-PCR,
reverse transcriptase-polymerase chain reaction; VPF/VEGF,
vascular permeability factor/vascular endothelial growth factor.
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